Leonard Frank X
Officer at NVCR
- Sold, on record
- $13.3M
- Dollars the filings state
- Form 4 sales
- 30
- Latest Jun 4, 2026
- Form 144 notices
- 10
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- NVCRNovoCure LtdOfficer
Sales by reason
Form 4 sales per year, every sale on record.
Timeline
- 1 Form 4 sale NVCRUnusualJun 2, 2025 2025
Sold 30,196 shares at $17.50 ($528k)
Leonard Frank X, EVP, Pres., Novocure Oncology
10b5-1 planSold 15.2% of holdings ($3.5M position)168,452 shares left12x usual sizeFollows a Form 144Filing
- 2 Form 144 notice NVCRNoticeFeb 27, 2026 +270 days
Filed to sell 9,734 shares ($133k)
Leonard Frank X, Officer
No 10b5-1 plan3.9x usual sizeFiling
- 3 Form 144 notice NVCRNoticeMar 2, 2026 +3 days
Filed to sell 7,232 shares ($98k)
Leonard Frank X, Officer
No 10b5-1 plan2.9x usual sizeFiling
- 4 Form 4 sale NVCRUnusualMar 2, 2026 same day
Sold 16,966 shares at $13.59 ($231k)
Leonard Frank X, Chief Executive Officer
No 10b5-1 planSold 4.6% of holdings ($5M position)349,400 shares left6.7x usual sizeFollows a Form 144Filing
- 5 Form 144 notice NVCRNoticeMar 4, 2026 +2 days
Filed to sell 5,607 shares ($75k)
Leonard Frank X, Officer
No 10b5-1 plan0.6x usual sizeFiling
- 6 Form 4 sale NVCRNo planMar 4, 2026 same day
Sold 5,607 shares at $13.31 ($75k)
Leonard Frank X, Chief Executive Officer
No 10b5-1 planSold 1.1% of holdings ($6.6M position)493,793 shares left0.4x usual sizeFollows a Form 144Filing
- 7 Form 144 notice NVCRNoticeJun 4, 2026 +92 days
Filed to sell 34,273 shares ($615k)
Leonard Frank X, Officer
No 10b5-1 plan3.3x usual sizeFiling
- 8 Form 4 sale NVCRUnusualJun 4, 2026 same day
Sold 34,273 shares at $17.93 ($615k)
Leonard Frank X, Chief Executive Officer
No 10b5-1 planSold 6.9% of holdings ($8.9M position)459,520 shares left3.3x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (40)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Jun 5, 2026 | NVCR | Chief Executive Officer | Form 4 sale | 34,273 | $615k | 6.9% | Unusual | SEC |
| Jun 4, 2026 | Jun 4, 2026 | NVCR | Officer | Form 144 notice | 34,273 | $615k | Notice | SEC | |
| Mar 4, 2026 | Mar 5, 2026 | NVCR | Chief Executive Officer | Form 4 sale | 5,607 | $75k | 1.1% | No plan | SEC |
| Mar 4, 2026 | Mar 4, 2026 | NVCR | Officer | Form 144 notice | 5,607 | $75k | Notice | SEC | |
| Mar 2, 2026 | Mar 3, 2026 | NVCR | Chief Executive Officer | Form 4 sale | 16,966 | $231k | 4.6% | Unusual | SEC |
| Mar 2, 2026 | Mar 2, 2026 | NVCR | Officer | Form 144 notice | 7,232 | $98k | Notice | SEC | |
| Feb 27, 2026 | Feb 27, 2026 | NVCR | Officer | Form 144 notice | 9,734 | $133k | Notice | SEC | |
| Jun 2, 2025 | Jun 4, 2025 | NVCR | EVP, Pres., Novocure Oncology | Form 4 sale | 30,196 | $528k | 15.2% | Unusual | SEC |
| Jun 2, 2025 | Jun 2, 2025 | NVCR | Officer | Form 144 notice | 30,196 | $577k | Notice | SEC | |
| Mar 3, 2025 | Mar 4, 2025 | NVCR | EVP, Pres., Novocure Oncology | Form 4 sale | 2,527 | $47k | 1.7% | No plan | SEC |
| Mar 3, 2025 | Mar 3, 2025 | NVCR | Officer | Form 144 notice | 2,527 | $47k | Notice | SEC | |
| Feb 28, 2025 | Mar 3, 2025 | NVCR | EVP, Pres., Novocure Oncology | Form 4 sale | 15,036 | $296k | 9.3% | Unusual | SEC |
| Feb 28, 2025 | Feb 28, 2025 | NVCR | Officer | Form 144 notice | 2,770 | $51k | Notice | SEC | |
| Feb 27, 2025 | Feb 27, 2025 | NVCR | Officer | Form 144 notice | 12,266 | $246k | Notice | SEC | |
| Nov 1, 2024 | Nov 4, 2024 | NVCR | EVP, Pres., Novocure Oncology | Form 4 sale | 598 | $10k | 0.4% | No plan | SEC |
| Mar 4, 2024 | Mar 5, 2024 | NVCR | EVP, Pres., Novocure Oncology | Form 4 sale | 2,519 | $40k | 1.5% | No plan | SEC |
| Mar 4, 2024 | Mar 4, 2024 | NVCR | Officer | Form 144 notice | 840 | $13k | Notice | SEC | |
| Mar 1, 2024 | Mar 1, 2024 | NVCR | Officer | Form 144 notice | 1,679 | $27k | Notice | SEC | |
| Feb 28, 2024 | Feb 29, 2024 | NVCR | EVP, Pres., Novocure Oncology | Form 4 sale | 2,078 | $34k | 1.3% | No plan | SEC |
| Mar 7, 2023 | Mar 7, 2023 | NVCR | President, CNS Cancers US | Form 4 sale | 13,609 | $1M | 20.0% | Unusual | SEC |
| Mar 3, 2023 | Mar 6, 2023 | NVCR | President, CNS Cancers US | Form 4 sale | 2,903 | $223k | 4.1% | Plan not stated | SEC |
| Mar 2, 2023 | Mar 3, 2023 | NVCR | President, CNS Cancers US | Form 4 sale | 4,107 | $310k | 6.5% | Plan not stated | SEC |
| Mar 1, 2023 | Mar 2, 2023 | NVCR | President, CNS Cancers US | Form 4 sale | 1,684 | $129k | 2.6% | Plan not stated | SEC |
| Jan 5, 2023 | Jan 9, 2023 | NVCR | President, CNS Cancers US | Form 4 sale | 39,507 | $4.4M | 46.1% | Unusual | SEC |
| Oct 13, 2022 | Oct 17, 2022 | NVCR | President, CNS Cancers US | Form 4 sale | 6,754 | $513k | 13.4% | Unusual | SEC |
| Oct 6, 2022 | Oct 7, 2022 | NVCR | President, CNS Cancers US | Form 4 sale | 6,754 | $570k | 11.8% | Unusual | SEC |
| Sep 29, 2022 | Sep 30, 2022 | NVCR | President, CNS Cancers US | Form 4 sale | 6,754 | $522k | 10.6% | Unusual | SEC |
| Sep 22, 2022 | Sep 26, 2022 | NVCR | President, CNS Cancers US | Form 4 sale | 6,754 | $520k | 9.6% | Unusual | SEC |
| Sep 15, 2022 | Sep 19, 2022 | NVCR | Chief Development Officer | Form 4 sale | 12,271 | $1.1M | 14.8% | Unusual | SEC |
| Sep 9, 2022 | Sep 12, 2022 | NVCR | Chief Development Officer | Form 4 sale | 1,863 | $164k | 2.2% | Plan not stated | SEC |
| Sep 6, 2022 | Sep 7, 2022 | NVCR | Chief Development Officer | Form 4 sale | 1,384 | $109k | 1.6% | Plan not stated | SEC |
| Sep 2, 2022 | Sep 6, 2022 | NVCR | Chief Development Officer | Form 4 sale | 14,796 | $1.1M | 14.5% | Unusual | SEC |
| Aug 2, 2022 | Aug 3, 2022 | NVCR | Chief Development Officer | Form 4 sale | 414 | $29k | 0.4% | Plan not stated | SEC |
| Mar 8, 2022 | Mar 9, 2022 | NVCR | Chief Development Officer | Form 4 sale | 744 | $52k | 0.7% | Plan not stated | SEC |
| Mar 4, 2022 | Mar 7, 2022 | NVCR | Chief Development Officer | Form 4 sale | 1,485 | $108k | 1.4% | Plan not stated | SEC |
| Sep 2, 2021 | Sep 7, 2021 | NVCR | Chief Development Officer | Form 4 sale | 540 | $75k | 0.6% | Plan not stated | SEC |
| Aug 3, 2021 | Aug 4, 2021 | NVCR | Chief Development Officer | Form 4 sale | 1,041 | $156k | 1.2% | Plan not stated | SEC |
| Mar 8, 2021 | Mar 10, 2021 | NVCR | Chief Development Officer | Form 4 sale | 765 | $100k | 0.8% | Plan not stated | SEC |
| Mar 4, 2021 | Mar 8, 2021 | NVCR | Chief Development Officer | Form 4 sale | 567 | $78k | 0.6% | Plan not stated | SEC |
| Mar 2, 2021 | Mar 4, 2021 | NVCR | Chief Development Officer | Form 4 sale | 430 | $65k | 0.5% | Plan not stated | SEC |